What is the recommended antiretroviral regimen and opportunistic infection prophylaxis for an HIV‑positive patient with a CD4 count below 200 cells/µL?

HIV Treatment for Low CD4 Count (<200 cells/µL)

For HIV-positive patients with CD4 counts below 200 cells/µL, initiate antiretroviral therapy immediately with a three-drug integrase strand transfer inhibitor (INSTI)-based regimen—specifically bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir plus tenofovir/lamivudine (TXF/XTC)—and start Pneumocystis jirovecii pneumonia (PCP) prophylaxis with trimethoprim-sulfamethoxazole. 1

Antiretroviral Therapy Selection

First-Line Regimen Choice

The 2025 IAS-USA guidelines prioritize INSTI-based three-drug regimens as the standard of care 1. For patients with CD4 <200 cells/µL:

• Preferred regimens:

  • Bictegravir/emtricitabine/tenofovir alafenamide (single-tablet)
  • Dolutegravir plus tenofovir/lamivudine

• Alternative regimens (if INSTI cannot be used):

  • Darunavir/cobicistat/tenofovir alafenamide/emtricitabine
  • Darunavir/cobicistat plus tenofovir disoproxil fumarate/lamivudine 2

Critical Caveat About Two-Drug Regimens

Avoid dolutegravir/lamivudine (two-drug regimen) in patients with CD4 <200 cells/µL. The GEMINI studies showed numerically lower viral suppression rates in this population (79% vs 93% with three-drug regimens), though only 8% of study participants had CD4 counts this low 2. The limited data in severely immunosuppressed patients makes three-drug regimens the safer choice.

Why INSTI-Based Regimens Are Superior

Research demonstrates that INSTI-based regimens achieve better immune reconstitution in severely immunosuppressed patients. INSTI use is associated with higher rates of CD4/CD8 ratio recovery and normalization compared to NNRTI- or PI-based regimens 3. This translates to better immune restoration, which is critical when starting with advanced disease.

Opportunistic Infection Prophylaxis

Primary Prophylaxis Requirements at CD4 <200 cells/µL

Pneumocystis jirovecii pneumonia (PCP):

• Start: Trimethoprim-sulfamethoxazole (TMP-SMX) one double-strength tablet daily
• Alternative: TMP-SMX one single-strength tablet daily, or dapsone, atovaquone, or aerosolized pentamidine if sulfa-allergic 4

Toxoplasma gondii encephalitis (if IgG positive):

• TMP-SMX double-strength daily provides dual coverage for both PCP and toxoplasmosis
• If using alternative PCP prophylaxis, add dapsone plus pyrimethamine plus leucovorin 4

Additional Prophylaxis Considerations

At CD4 <100 cells/µL, add:

• Consider toxoplasmosis prophylaxis if not already covered by TMP-SMX

At CD4 <50 cells/µL, add:

• Mycobacterium avium complex (MAC) prophylaxis: Azithromycin 1200 mg weekly or clarithromycin 500 mg twice daily 4

Monitoring CD4 Percentage

Pay attention to both absolute CD4 count and CD4 percentage. Patients with CD4 count >200 but CD4% <14% should also receive PCP prophylaxis, as discordance occurs in 13-16% of patients and carries similar risk 5. Providers frequently miss this—don't rely solely on absolute count.

Treatment Initiation Strategy

Immediate ART Initiation

Start ART immediately upon diagnosis, even before resistance testing results return, using one of the recommended three-drug INSTI regimens 1. The benefits of rapid viral suppression and immune reconstitution outweigh the small risk of transmitted resistance in this population.

Baseline Testing Before ART

• HIV genotype resistance testing (but don't delay ART for results)
• Hepatitis B surface antigen (HBsAg) and hepatitis C antibody
• Complete blood count, comprehensive metabolic panel
• CD4 count and HIV viral load
• Pregnancy test if applicable
• HLA-B*5701 testing only if considering abacavir (which is not preferred) 2

Special Populations and Situations

Tuberculosis Co-infection

If active TB is present or suspected with rifamycin treatment planned:

• Use dolutegravir 50 mg twice daily (not once daily) with rifamycin-containing TB regimens 1
• Bictegravir may be considered as alternative if dolutegravir cannot be used
• If neither INSTI works: ritonavir-boosted atazanavir or lopinavir with TXF/XTC plus rifabutin 150 mg daily 1

Hepatitis B Co-infection

Ensure the NRTI backbone includes agents active against HBV:

• Use tenofovir (alafenamide or disoproxil fumarate) plus emtricitabine or lamivudine
• Never use dolutegravir/lamivudine two-drug regimen in HBV co-infection—lamivudine monotherapy risks HBV resistance 2

Cancer Diagnosis

For newly diagnosed HIV with cancer and no prior ART, start ART immediately 1. Coordinate closely with oncology regarding drug-drug interactions between ART and chemotherapy/immunotherapy. Some cancer treatments may further suppress CD4 counts, requiring reassessment of OI prophylaxis needs even after immune reconstitution.

Monitoring and Follow-Up

Initial Monitoring Schedule

• HIV viral load at 4 weeks, then every 4-8 weeks until undetectable
• CD4 count at 3 months, then every 3-6 months
• Assess adherence and tolerability at each visit
• Monitor for immune reconstitution inflammatory syndrome (IRIS), especially in first 3 months

When to Discontinue Prophylaxis

PCP prophylaxis can be stopped when:

• CD4 count rises above 200 cells/µL for at least 3 months on ART
• HIV viral load is undetectable 6, 4

MAC prophylaxis can be stopped when:

• CD4 count rises above 100 cells/µL for at least 3 months on ART
• HIV viral load is suppressed 4

Common Pitfalls to Avoid

1. Don't use two-drug regimens (dolutegravir/lamivudine) in patients with CD4 <200 cells/µL—insufficient data and numerically worse outcomes 2

2. Don't forget CD4 percentage—absolute count and percentage discordance occurs in 13% of patients, and those with CD4% <14% need prophylaxis even if absolute count >200 5

3. Don't delay ART for resistance testing results—start immediately with recommended regimen; transmitted resistance to INSTIs remains rare

4. Don't overlook hepatitis B screening—affects NRTI selection and prevents use of certain two-drug regimens 2

5. Don't forget MAC prophylaxis at CD4 <50 cells/µL—frequently overlooked but prevents significant morbidity 4

6. Don't interpret hospitalized CD4 counts at face value—acute illness, sepsis, and stress can transiently suppress lymphocyte counts; use CD4% and clinical context 7